Pharma Stocks Outlook for the week - 30.01.2017 to 03.02.2017
Pharma Stocks Outlook for the week - 30.01.2017 to 03.02.2017
( www.rupeedesk.in )
Stocks of pharmaceutical companies, sentiment is likely to remain positive early next week, though the Union Budget for 2017-18 (Apr-Mar) will be the key factor to watch. We expects Finance Minister Arun Jaitley to allow 100% deduction on approved expenditure incurred for securing accreditation from the National Accreditation Board for Hospitals and Healthcare Providers, and the National Accreditation Board for Testing and Calibration Laboratories. This would aid pharmaceutical companies Sun Pharmaceutical Industries, Alkem Laboratories, and Lupin. It also expects the status of the healthcare sector to be changed from priority sector to infrastructure sector, which would considerably reduce the cost of borrowing for companies. Industry participants expect the finance minister to provide incentives to companies for research and development, and increase tax sops for medical expenses. All excisable goods used for R&D should be exempted from central excise duty expects such a move by the government to boost spending by companies on research and development. Next week, investors will also look forward to the earnings of Cadila Healthcare, Glenmark Pharmaceuticals, and Pfizer. In the US market, which accounts for the bulk of sales for pharmaceutical companies, investors will look at President Donald Trump's actions. Earlier, Trump had raised concern on the high prices of drugs. Any action to curb these will put pressure on prices in the US, which are already weighed down by consolidation of distribution channels there.
Free Intraday Tips : Join Our Whatsapp No : 9841986753
Free Commodity Tips : Join our Whatsapp No : 9094047040
Pharma Stocks Outlook for the week - 30.01.2017 to 03.02.2017
( www.rupeedesk.in )
Stocks of pharmaceutical companies, sentiment is likely to remain positive early next week, though the Union Budget for 2017-18 (Apr-Mar) will be the key factor to watch. We expects Finance Minister Arun Jaitley to allow 100% deduction on approved expenditure incurred for securing accreditation from the National Accreditation Board for Hospitals and Healthcare Providers, and the National Accreditation Board for Testing and Calibration Laboratories. This would aid pharmaceutical companies Sun Pharmaceutical Industries, Alkem Laboratories, and Lupin. It also expects the status of the healthcare sector to be changed from priority sector to infrastructure sector, which would considerably reduce the cost of borrowing for companies. Industry participants expect the finance minister to provide incentives to companies for research and development, and increase tax sops for medical expenses. All excisable goods used for R&D should be exempted from central excise duty expects such a move by the government to boost spending by companies on research and development. Next week, investors will also look forward to the earnings of Cadila Healthcare, Glenmark Pharmaceuticals, and Pfizer. In the US market, which accounts for the bulk of sales for pharmaceutical companies, investors will look at President Donald Trump's actions. Earlier, Trump had raised concern on the high prices of drugs. Any action to curb these will put pressure on prices in the US, which are already weighed down by consolidation of distribution channels there.
